Category: Biolase Technology Inc.
Smith & Nephew appoints Stéphane Thiroloix as president of its European advanced surgical devices division.
British health care giant Smith & Nephew (NYSE:SNN) named industry veteran Stéphane Thiroloix as president of its European advanced surgical devices division.
Thiroloix will be based in Baar, Switzerland, and will be responsible for leading and directing all commercial activities in the advanced surgical devices division, specifically the markets focused on orthopedics and sports medicine.
InVivo Therapeutics appoints spinal cord injury expert Dr. Edward Wirth as its new chief scientific officer.
InVivo Therapeutics Holdings Corp. (OTC:NVIV) appointed spinal cord injury expert Dr. Edward Wirth as its new chief scientist.
InVivo brings Wirth to the team as its waiting for a green light by the FDA to begin human trials of its biodegradable scaffold for treating spinal cord injury.
The scaffold is designed to protect and support spinal tissue and prevent secondary injury, including inflammation and glial scarring, following traumatic spinal cord injury.
Biomet Inc. reports wider fourth-quarter and full-year losses on a nearly $1 billion writedown and sluggish U.S. sales.
Losses for Biomet Inc., a bellwether for the U.S. orthopedic market, soared during the fourth quarter and fiscal 2011, largely due to a nearly $1 billion writedown related to its re-assessment of the European market.
Mendor, a Finish diabetes tech company rounds up nearly $2 million in a Series B funding round.
Mendor, a Finish diabetes technologies and services company, raised $11.7 million in a Series B financing round, aiming for global expansion.
Funding was led by Finnish entrepreneur and investor Risto Siilasmaa, joined by Life Sciences Partners (LSP), Finnish Industry Investment Ltd., Finnish Mutual Pension Insurance Company Ilmarinen, private Finnish investment group Biothom and the Finnvera Venture Capital as a returning investor.
Biolase retains the right to market its iLase cordless dental laser after settling a patent infringement lawsuit filed by Philips Healthcare's Discus Dental subsidiary.
Biolase Technology Inc. (NSDQ:BLTI) kept the right to sell a cordless laser for dentists after settling a lawsuit with Discuss Dental, a Royal Philips Electronics (NYSE:PHG) subsidiary.
Discus claimed in April 2010 that Irvine, Calif.-based Biolase's iLase device violated a Discus design patent.
Taris Biomedical Inc. completes an $18.3 million B round that the company says will support the clinical development of its bladder disorder treatment drug-device combination.
Taris Biomedical Inc. drummed up $18.3 million in its latest funding round.
Lexington, Mass.-based company said the equity-based B round will support its lidocaine delivery technology developed at MIT to treat bladder conditions.
Third Rock Ventures, a new backer for the company, led the round, and previous investors Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners also participated in the financing.
Dental laser-maker Biolase Technology earns its ninth patent for optical-related procedures, prompting share prices to climb 16 percent.
Biolase Technology Inc. (NSDQ:BLTI) stock is getting a big boost today, with shares climbing more than 16 percent to reach their best levels since June 2008 after the company received a U.S. patent for tools that make it easier to see structures inside the eye.